Cel-Sci Price to Book Ratio 2006-2021 | CVM

Historical price to book ratio values for Cel-Sci (CVM) over the last 10 years. The current price to book ratio for Cel-Sci as of October 26, 2021 is 8.12.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Cel-Sci Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-26 11.36 8.16
2021-06-30 8.68 $1.39 6.24
2021-03-31 15.21 $0.72 21.17
2020-12-31 11.66 $0.73 16.08
2020-09-30 12.75 $0.51 25.03
2020-06-30 14.92 $0.54 27.52
2020-03-31 11.54 $0.38 30.47
2019-12-31 9.15 $0.25 36.78
2019-09-30 8.94 $0.15 61.36
2019-06-30 8.38 $0.03 249.40
2019-03-31 3.54 $0.03 110.97
2018-12-31 2.87 $0.10 29.50
2018-09-30 4.05 $0.00 0.00
2018-06-30 0.92 $-0.06 -14.38
2018-03-31 1.41 $-0.18 -7.66
2017-12-31 1.89 $-0.36 -5.18
2017-09-30 1.66 $-0.28 -5.92
2017-06-30 2.23 $-0.55 -4.04
2017-03-31 2.14 $-0.33 -6.54
2016-12-31 1.68 $0.61 2.73
2016-09-30 7.63 $-0.11 -70.15
2016-06-30 11.50 $-0.65 -17.69
2016-03-31 13.25 $-0.54 -24.33
2015-12-31 9.25 $0.68 13.63
2015-09-30 15.00 $-1.06 -14.15
2015-06-30 16.50 $0.88 18.83
2015-03-31 26.25 $0.09 280.15
2014-12-31 14.53 $3.24 4.49
2014-09-30 22.79 $3.19 7.15
2014-06-30 31.00 $5.69 5.45
2014-03-31 38.00 $3.16 12.04
2013-12-31 14.80 $6.76 2.19
2013-09-30 42.50 $5.40 7.87
2013-06-30 53.28 $6.29 8.47
2013-03-31 57.63 $9.33 6.17
2012-12-31 67.50 $9.41 7.18
2012-09-30 86.25 $6.43 13.41
2012-06-30 93.95 $8.26 11.38
2012-03-31 120.00 $6.08 19.73
2011-12-31 72.48 $8.82 8.22
2011-09-30 91.25 $10.57 8.63
2011-06-30 124.43 $10.90 11.41
2011-03-31 157.50 $12.81 12.30
2010-12-31 205.25 $27.76 7.39
2010-09-30 161.00 $33.99 4.74
2010-06-30 122.50 $42.35 2.89
2010-03-31 162.50 $42.41 3.83
2009-12-31 225.00 $41.34 5.44
2009-09-30 430.00 $11.51 37.35
2009-06-30 100.63 $18.64 5.40
2009-03-31 60.00 $19.04 3.15
2008-12-31 71.25 $20.60 3.46
2008-09-30 100.00 $22.43 4.46
2008-06-30 165.00 $20.59 8.01
2008-03-31 170.00 $23.74 7.16
2007-12-31 127.48 $30.46 4.18
2007-09-30 156.30 $31.70 4.93
2007-06-30 185.00 $28.50 6.49
2007-03-31 190.00 $-10.67 -17.81
2006-12-31 140.00 $-5.43 -25.78
2006-09-30 155.00 $-2.81 -55.10
2006-06-30 215.00 $7.59 28.33
2006-03-31 182.50 $8.10 22.54
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.489B $0.001B
CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86